The point-of-care (POC) molecular diagnostics market is steadily expanding, with a compound annual growth rate (CAGR) of approximately 6%. This growth is fueled by a growing need for fast, ...

“There is strong appetite for high-growth, profitable diagnostic companies, and we believe this should continue given the sector's macro backdrop,” William Blair’s Andrew Brackmann wrote in a research ...

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...

Molecular Instruments, Inc. announced today that the Unified Patent Court (UPC) of the European Union has found that Molecular Instruments' HCR(TM) RNA-ISH technology does not infringe two patents ...

Foresight’s technology will be integrated into Natera’s Signatera platform and is expected to be launched for clinical use in ...

Hologic HOLX offers a wide range of diagnostic products to help in the screening and diagnosis of human disease. Although the performance of the Diagnostics segment in recent quarters has been ...

Hummingbird Diagnostics GmbH, a pioneer in harnessing blood-based small RNAs for early disease detection and characterization, today announced the publication of a new study in Nature Communications ...

This Nature Outlook is editorially independent, produced with financial support from Seegene. About this content. Working out what ails a person is a founding principle of modern medicine. And as ...

We searched for evidence from studies known as 'clinical trials' that compared rapid TB tests with traditional methods of testing for TB, like smear microscopy and culture. We summarised the findings ...

The diagnostic armamentarium for solid tumors is evolving rapidly, redefining how we detect, stage, stratify, monitor, and ultimately treat cancer. This ...

The firm's Phase I/II study yielded responses in mCRPC patients with androgen receptor mutations but it wasn't as promising in HR-positive breast cancer.